Mark Arnold
About Mark Arnold
Mark Arnold is the Managing Director at Bioanalytical Solution Integration and holds director positions at Labcorp Drug Development and Covance. He has extensive experience in the pharmaceutical industry, including a long tenure at Bristol-Myers Squibb and a Ph.D. in Pharmacology & Toxicology from the University of Pittsburgh.
Current Roles
Mark Arnold holds multiple high-level positions across various pharmaceutical and bioanalytical companies. He is the Managing Director at Bioanalytical Solution Integration in Burlington, NJ, and the Director of Science at Labcorp Drug Development in Westampton, NJ. Additionally, he serves as the Director - Site Lead at Covance in West Trenton, NJ.
Career History at Bristol-Myers Squibb
Mark Arnold had a significant tenure at Bristol-Myers Squibb spanning over two decades. He started as a Research Investigator in 1986 and held roles such as Senior Research Investigator, Group Leader, Associate Director, Director, Group Director, and Executive Director. His last position at the company was as Executive Director, serving from 2013 to 2016 in Princeton, NJ.
Previous Experience
Prior to his longstanding career at Bristol-Myers Squibb, Mark Arnold gained experience at various organizations. He worked at Schering-Plough Animal Health Research Center as a Senior Scientist in 1985-1986, Union Carbide Corporation as a Consultant in 1982, and served as a Teaching Fellow at the University of Pittsburgh from 1980 to 1985. Earlier in his career, he held an intern position at Rochester and Pittsburgh Coal Company in 1979.
Educational Background
Mark Arnold completed his Ph.D. in Pharmacology & Toxicology at the University of Pittsburgh from 1981 to 1985. Prior to that, he earned his B.S. in Biology from Indiana University of Pennsylvania, graduating in 1980.
Professional Involvement and Recognitions
Mark Arnold was inducted as an AAPS Fellow in 2014. He is the founder and a Steering Committee member of the Global Bioanalysis Consortium and has been actively involved in the Bioanalytical Focus Group of the AAPS, previously serving as its Chair. Additionally, he has served as the Scientific Program Chair for the PharmSci360 Conference and is engaged in the Land O'Lakes Bioanalytical Meeting's Programming Committee.